- Home
- LYEL vs LFMDP Comparison
LYEL vs LFMDP Comparison
Compare LYEL & LFMDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | LFMDP |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | 384 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | N/A |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYEL | LFMDP |
|---|---|---|
| Price | $20.81 | $24.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.25 | N/A |
| AVG Volume (30 Days) | ★ 80.2K | 1.6K |
| Earning Date | 03-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,438.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $18.50 |
| 52 Week High | $45.00 | $25.25 |
Technical Indicators
Market Signals| Indicator | LYEL | LFMDP |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 68.93 |
| Support Level | $16.20 | $23.95 |
| Resistance Level | $27.30 | $24.19 |
| Average True Range (ATR) | 2.02 | 0.31 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 41.28 | 100.00 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About LFMDP LifeMD Inc.
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.